Are FDA-approved hormones bioidentical?

Many are. Estradiol patches, gels, sprays, tablets, vaginal creams, inserts, and the vaginal ring all contain 17-beta estradiol, which is molecularly identical to the estrogen your ovaries produced. Micronized progesterone capsules are bioidentical progesterone, and an approved combination capsule pairs estradiol with progesterone. If someone tells you bioidentical hormones require a compounding pharmacy, that is not accurate.

Did ACOG say compounded bioidentical hormones are unsafe?

ACOG's Clinical Consensus recommends FDA-approved hormone therapy over compounded preparations for most women, which is a different statement from declaring compounded hormones unsafe. The objections are that compounded preparations lack verified potency, do not come with standardized labeling and warnings, and have no evidence base supporting the superiority claims made for them. ACOG accepts compounding for a documented allergy to an ingredient in an approved product, or a needed dose or formulation that is not commercially available.

Why do compounding clinics use saliva testing if it isn't validated?

Saliva testing produces a personalized-looking result that supports a custom formulation and a retesting schedule. Clinically, it does not work as a dosing tool: salivary hormone concentrations fluctuate substantially within a single day and do not reliably reflect serum levels. Menopausal hormone therapy is dosed to symptom response, not to a target number. ACOG does not support salivary testing for determining hormone therapy dosing.

Are hormone pellets FDA-approved?

Estradiol and estradiol-testosterone pellets marketed to menopausal women are compounded and not FDA-approved. There is an approved testosterone pellet in the US, but it is approved for men. The specific concern with any pellet is that the dose cannot be reduced or stopped once implanted without a procedure to remove it, and compounded pellets have been associated with hormone levels above the premenopausal physiologic range.

Can I get testosterone as a woman in the US without compounding?

Not from an approved female product, because none exists in the US. Women prescribed testosterone receive either a compounded preparation or a measured fraction of a product approved for men. The Global Consensus Position Statement supports testosterone for postmenopausal hypoactive sexual desire disorder specifically, at doses approximating premenopausal physiologic levels, with blood levels checked to confirm the dose has not overshot. It does not support testosterone for fatigue, mood, cognition, or general wellbeing in women.

What about estriol and "Bi-Est" or "Tri-Est" formulas?

Estriol is not an FDA-approved active ingredient in the United States, so any preparation containing it is compounded by definition. Multi-estrogen blends are marketed on the theory that reproducing several estrogens is more physiologic, but the National Academies review found the evidence insufficient to support the clinical utility of compounded bioidentical preparations generally, and that includes these formulas.

Is bioidentical hormone therapy safer than conventional HRT?

The comparison is often made incorrectly. Route and molecule do appear to matter — NAMS's 2022 position statement describes benefit and risk as depending on hormone type, dose, route, duration, timing of initiation, and whether a progestogen is required. But those distinctions apply to approved estradiol and micronized progesterone, which are bioidentical and approved. Being compounded adds no safety advantage; it removes the verification and labeling that approved products carry.

How do I ask whether what I'm being prescribed is FDA-approved?

Ask it as a direct question about the finished product, not the ingredients: "Is this specific product FDA-approved, or is it compounded?" Then ask where the prescription will be filled — a compounding pharmacy name is the practical tell. ACOG's consensus asks clinicians to disclose non-approved status explicitly, so a clear answer is a reasonable expectation, not an awkward request.

If I'm already on compounded hormones and feel fine, should I switch?

Feeling well is meaningful information and not something to discard. The reason to raise it with a clinician is that an approved equivalent usually exists for the same molecules, often costs less, comes with verified dosing, and — if you have a uterus — provides established endometrial protection. That is a conversation about substituting a known quantity for an unverified one, not about stopping treatment. Do not stop or change hormone therapy on your own.

BHRT · Myth vs fact

Bioidentical Hormones: What the Word Means, and the Two Very Different Things It Is Used to Sell

Educational guide · By ClearHormones Editorial Team · Updated July 2026

"Bioidentical" describes a hormone molecule that is structurally identical to the one your ovaries made — estradiol rather than a conjugated equine estrogen, micronized progesterone rather than a synthetic progestin. That is a chemistry statement, and nothing more. It says nothing about who made the product, whether the dose in the container matches the dose on the label, or whether anyone has tested it for safety. This is the single most important thing to understand about the word: it is a description of a molecule, not a category of quality.

Key takeaways

"Bioidentical" is a statement about molecular structure, not about safety, testing, or manufacturing quality — FDA-approved estradiol and micronized progesterone are bioidentical.
ACOG's Clinical Consensus recommends FDA-approved hormone therapy over compounded preparations for most women, reserving compounding for documented allergy to an ingredient or a dose or route not commercially available.
The National Academies review found the evidence insufficient to support the clinical utility of compounded bioidentical hormone therapy for routine use.
Salivary hormone testing is not a validated way to dose menopausal hormone therapy; symptoms, not levels, guide dosing in every major guideline.
Compounded pellets are the formulation with the most specific objections: dose cannot be adjusted or removed once implanted, and levels can run above the physiologic range.
There is no FDA-approved testosterone product for women in the US, which is the one common situation where compounding or off-label use of a male product is genuinely unavoidable.

The short answer

In practice, American women encounter "bioidentical" in two settings that could hardly be more different. The first is a shelf of FDA-approved, mass-manufactured products — estradiol patches, gels, sprays, vaginal inserts and rings, and micronized progesterone capsules — that are bioidentical by molecule and have gone through the full approval process, with batch-to-batch consistency, standardized labeling, and post-market surveillance. The second is compounded bioidentical hormone therapy (cBHT): custom preparations mixed by a compounding pharmacy, often as creams, troches, or subcutaneous pellets, frequently dosed from saliva or blood tests, and sold with claims of individualization. These products are not FDA-approved, not required to carry the same labeling, and not subject to the same manufacturing verification.

Both major bodies that examined this in the last several years came to the same place. The American College of Obstetricians and Gynecologists' Clinical Consensus on compounded bioidentical menopausal hormone therapy recommends FDA-approved hormone therapy for most women and reserves compounding for specific documented circumstances. The National Academies of Sciences, Engineering, and Medicine reached a parallel conclusion, finding the evidence insufficient to support routine clinical use of cBHT and recommending it be restricted to patients who genuinely cannot use an approved product. If you want bioidentical hormones, you can almost always get them with an FDA approval attached.

What "bioidentical" actually means, stripped of marketing

A bioidentical hormone has the same molecular structure as a hormone your body produces. 17-beta estradiol is bioidentical estrogen. Micronized progesterone is bioidentical progesterone. Testosterone is testosterone. That is the whole definition.

The word gained traction because it sounds like the opposite of "synthetic," but the contrast is false in both directions. Bioidentical hormones are synthesized in a laboratory — usually from plant sterols found in soy or yams — and then chemically converted. Your body cannot convert wild yam cream into progesterone; that conversion happens in an industrial process, not in your skin. Meanwhile, a non-bioidentical hormone like medroxyprogesterone acetate is also made in a lab; it simply has a different structure and therefore different receptor behavior.

There is a real clinical reason to prefer body-identical molecules for some women — micronized progesterone and transdermal estradiol have a different metabolic and receptor profile from older oral synthetic combinations, and the North American Menopause Society's 2022 position statement discusses how route, formulation, dose, and timing all shape the benefit-risk picture. But that reasoning applies equally to an FDA-approved estradiol patch. Nothing about it requires a compounding pharmacy.

The same molecule, two very different supply chains
Question	FDA-approved body-identical	Compounded bioidentical (cBHT)
Is the molecule bioidentical?	Yes — estradiol, micronized progesterone, testosterone	Yes — same molecules, sometimes plus estriol
Reviewed for safety and efficacy before sale?	Yes, through the FDA approval process	No
Batch-to-batch dose consistency verified?	Yes, under manufacturing standards	Not verified the same way; potency can vary
Standardized labeling and boxed warnings?	Yes	Not required in the same form
Adverse events tracked post-market?	Yes, through FDA surveillance	No comparable system
Typically covered by insurance?	Often	Usually cash-pay

The FDA-approved bioidentical products most women do not know exist

A frequent reason women end up at a compounding clinic is the belief that "real" bioidentical hormones are only available custom-made. They are not. The approved US market includes 17-beta estradiol in transdermal patches, topical gels, emulsions and sprays, oral tablets, vaginal creams, vaginal inserts, and a vaginal ring — the prescribing information for the estradiol vaginal ring, for example, is a public FDA document. Micronized progesterone is available as an approved oral capsule. There is also an approved combination capsule pairing estradiol with progesterone.

That covers the great majority of clinical needs: systemic estrogen for hot flashes and night sweats, progesterone for endometrial protection, and local vaginal estrogen for genitourinary symptoms. If a provider tells you that bioidentical estradiol or bioidentical progesterone requires compounding, that statement is factually wrong, and it is a useful signal about the rest of the conversation.

The genuine gaps in the approved US market are narrower than the marketing suggests: there is no approved testosterone product for women, estriol is not an approved active ingredient in the US, and certain unusual doses or vehicles do not exist commercially. Those gaps are where compounding has a legitimate role — and they are the exception, not the default.

What ACOG's Clinical Consensus concluded about cBHT

ACOG's Clinical Consensus on compounded bioidentical menopausal hormone therapy is unusually direct. Its central position is that FDA-approved hormone therapy should be used in preference to compounded preparations for the treatment of menopausal symptoms, because approved products carry evidence of efficacy, verified dosing, and standardized safety labeling that compounded products do not.

ACOG's specific concerns are practical rather than philosophical. Compounded preparations may deliver more or less hormone than intended, because potency is not verified the way it is for a manufactured drug. They generally are not dispensed with the same package labeling and warnings, which means a woman taking compounded estrogen may never be told, in writing, the risks she would have been told about with an approved product. And the marketing claim that compounded hormones are safer, more natural, or individualized in a way approved products are not is unsupported by evidence.

ACOG also addresses the testing question head-on: it does not support the use of salivary hormone testing to determine or adjust hormone therapy dosing. And it flags that patients frequently do not understand that what they are being given is not FDA-approved — a disclosure gap the consensus asks clinicians to close explicitly.

Where ACOG allows compounding is narrow and specific: a documented allergy to an ingredient in an approved product, or a dose or formulation that is not commercially available and is clinically needed.

What the National Academies report found

The National Academies of Sciences, Engineering, and Medicine were asked by the FDA to assess the clinical utility of compounded bioidentical hormone therapy — a full independent review rather than a specialty-society opinion. Its conclusion was that the available evidence is insufficient to support the general clinical use of cBHT preparations.

The report is worth understanding on its own terms because it was not arguing that compounded hormones are inherently dangerous molecules. It was pointing at an evidence vacuum: cBHT preparations have not been through the trials that establish efficacy and characterize risk, so no one — including the prescriber — can quote reliable numbers about what a given cream or pellet does over years of use. The report recommended that use be restricted to patients with a documented clinical need that an approved product cannot meet, and that prescribers and pharmacists do more to make patients aware of what is and is not known.

It also examined the marketing environment and found that claims made for cBHT — superiority, greater safety, individualization based on hormone level testing — are not backed by evidence. Two independent processes, ACOG's and the National Academies', looked at the same literature and arrived at the same restriction.

Why salivary hormone testing is not used to dose hormone therapy

A hallmark of the cBHT model is testing: saliva panels, sometimes dried urine or serial blood draws, followed by a custom formula "calibrated" to your results and periodic retesting. It is persuasive because it looks like precision medicine. The problem is that hormone levels are not the treatment target.

Menopausal hormone therapy is dosed to symptoms. You start at a reasonable dose, wait several weeks, and adjust based on whether hot flashes, night sweats, and sleep disruption have improved and whether side effects have appeared. NAMS's 2022 position statement and ACOG both frame dosing this way. There is no established therapeutic blood or saliva level for estradiol in a menopausal woman that a clinician should be titrating toward.

Salivary measurement has a specific additional problem: results vary substantially within the same person across a day, and they do not track reliably with the serum levels they are supposed to represent. When hormone concentrations themselves fluctuate hour to hour, a single reading tells you little. ACOG does not support salivary testing for this purpose.

There are narrow situations where laboratory hormone measurement genuinely matters — investigating primary ovarian insufficiency in a younger woman, working up abnormal bleeding, or checking a testosterone level to avoid supraphysiologic dosing. Those are diagnostic questions, not routine dose-titration for menopausal symptoms. If your treatment plan hinges on quarterly saliva panels, ask what decision the result will actually change.

The pellet question

Subcutaneous hormone pellets — implanted in the hip or buttock every few months — draw more specific objection than any other compounded format, and the reason is mechanical rather than ideological.

Once a pellet is implanted, the dose cannot be adjusted. If it turns out to be too high, there is no way to reduce it short of surgical removal, and the woman waits out the remaining months of release. Every other route of hormone therapy can be lowered or stopped the same day: a patch comes off, a capsule is not taken, a gel is not applied. Pellets remove that control at exactly the moment it is most needed.

The second issue is dose level. Compounded pellets, particularly testosterone pellets marketed to women, have been associated with hormone concentrations above the premenopausal physiologic range. The Global Consensus Position Statement on testosterone therapy for women is explicit that systemic dosing should aim to approximate premenopausal physiologic concentrations, and it does not support compounded formulations delivering supraphysiologic levels. Above that range, testosterone-related effects such as acne, unwanted hair growth, and voice change become more likely — and voice change may not fully reverse.

There is an approved testosterone pellet in the United States, but it is approved for men. Pellets containing estradiol, or estradiol-testosterone combinations, marketed for menopausal women are compounded products operating outside the approval framework.

When compounding is genuinely the right answer

Compounding pharmacies exist for real reasons and serve real patients. The problem is not compounding; it is compounding as a business model applied to women who had an approved option all along.

The legitimate cases share a structure: an FDA-approved product exists in principle but cannot be used by this specific patient, or does not exist at all in the needed form. A documented allergy to a dye, preservative, or carrier oil in an approved product is the standard example of a case where compounding is appropriate. So is a required dose that no manufacturer makes, or an inability to swallow a capsule or tolerate an adhesive patch.

The illegitimate cases also share a structure: the rationale is that compounded hormones are more natural, safer, better absorbed, or personalized to your lab results. None of those claims survived either the ACOG or National Academies review.

Sorting a compounding recommendation
Reason given for compounding	Does it hold up?
Documented allergy to an inactive ingredient in the approved product	Yes — this is the standard cited indication
Needed dose or route genuinely not commercially available	Yes, when the clinical need is documented
Testosterone for a woman in the US	Reasonable — no approved female product exists; dose to physiologic range
"Compounded is more natural / from plants"	No — approved estradiol and progesterone are also plant-derived and bioidentical
"Your saliva panel shows you need a custom ratio"	No — salivary testing is not supported for dosing
"Compounded is safer than FDA-approved hormones"	No — there is no evidence base establishing that
"Pellets are more convenient"	Convenience is real; the loss of dose adjustability is the trade-off
Estriol-containing creams	Estriol is not an FDA-approved active ingredient in the US

Testosterone: the one genuine gap in the US market

Testosterone is where the FDA-approved-only rule runs into a wall. No testosterone product is approved for women in the United States, so a woman who is a candidate for testosterone therapy is necessarily receiving either a compounded preparation or a fraction of a product approved for men. That is an evidence-based off-label situation, not a fringe one.

The evidence supports a narrow indication. A systematic review and meta-analysis in Lancet Diabetes & Endocrinology found that testosterone improved sexual function outcomes in postmenopausal women, and the Global Consensus Position Statement identifies hypoactive sexual desire disorder in postmenopausal women as the only indication with sufficient evidence to support use. The International Society for the Study of Women's Sexual Health clinical practice guideline addresses how this is applied in practice.

What the same documents do not support is testosterone for fatigue, mood, cognition, bone density, or general vitality in women — the claims most often used to justify pellets. They also emphasize dosing that approximates premenopausal physiologic levels, with baseline and follow-up testosterone measurement to confirm the level has not overshot. This is the one context where checking a hormone level is clearly indicated, and notably it is a safety check against overdosing, not a titration target.

Vaginal estrogen: bioidentical, approved, and routinely overlooked

Vaginal dryness, burning, painful sex, urinary urgency, and recurrent urinary tract infections after menopause fall under genitourinary syndrome of menopause. This is the symptom cluster that most often drives women toward custom compounded creams — and it is also the one with the strongest approved bioidentical options.

Low-dose vaginal estradiol is available in the US as approved creams, inserts, and a vaginal ring. NAMS's 2020 position statement on genitourinary syndrome of menopause covers this therapy class and the evidence that systemic absorption from low-dose vaginal preparations is minimal — which is the entire clinical point. A woman who does not want or cannot take systemic hormones may still be a candidate for local vaginal therapy.

Unlike hot flashes, which tend to remit eventually — research from the Study of Women's Health Across the Nation found that vasomotor symptoms commonly persist for years across the menopause transition rather than months — genitourinary symptoms are progressive and generally do not resolve on their own. That makes it worth getting the treatment right rather than cycling through compounded creams.

Endometrial protection is not optional, and cBHT complicates it

If you have a uterus and take systemic estrogen, you need adequate progestogen to protect the endometrial lining. Unopposed estrogen drives endometrial proliferation, and over time that raises the risk of hyperplasia and endometrial cancer. This is the single least negotiable rule in menopausal hormone therapy, and NAMS's 2022 position statement treats it as such.

Compounded regimens introduce two specific problems here. First, if the progesterone content of a compounded cream or troche is not what the label says — and potency verification is the documented weakness of compounded preparations — endometrial protection may be inadequate without anyone knowing. Second, transdermal and buccal progesterone routes have not been established as providing endometrial protection equivalent to oral micronized progesterone. A progesterone cream is not interchangeable with an approved oral capsule for this purpose.

The practical consequence: any bleeding after menopause, or a change in bleeding pattern while on hormone therapy, needs evaluation rather than reassurance. ACOG's guidance on postmenopausal bleeding and its committee opinion on the role of transvaginal ultrasonography describe how that evaluation proceeds. Do not let a compounded regimen become the reason bleeding gets explained away as "your body adjusting."

How to tell, in one appointment, which one you are being offered

The distinction is not always announced. Clinics offering compounded hormones frequently describe them simply as "bioidentical hormone therapy," which is technically accurate and tells you nothing. A few questions separate the two models quickly.

Ask whether the specific product being prescribed is FDA-approved. This is a yes-or-no fact, and a prescriber should answer it directly. If the answer is that the ingredients are FDA-approved, that is a different claim — an active ingredient can be approved while the finished preparation is not.

Ask where it will be filled. A regular retail pharmacy generally means an approved product; a specific named compounding pharmacy means cBHT. Ask whether the plan depends on saliva or serial hormone testing, and whether the dose can be lowered or stopped tomorrow if you do not tolerate it — the honest answer for a pellet is no.

Finally, ask what happens if an approved product would work. A clinician who can explain specifically why the approved option is unsuitable for you is practicing within the ACOG framework. One who cannot articulate a reason beyond individualization is selling a model.

Cost, insurance, and the economics that shape the advice

Approved hormone therapy is frequently covered by insurance, and several formulations are available as generics. Compounded preparations and pellet insertions are typically cash-pay, often through a subscription or package structure that bundles the initial hormone panel, the preparation, and scheduled retesting.

This matters clinically, not just financially. When retesting is a billable event inside the same practice that sells the preparation, the incentive to keep testing does not point in the same direction as the evidence — which says levels are not the dosing target for menopausal symptoms in the first place. That is worth naming when you evaluate a program that quotes an annual price.

It also means cost is a poor guide to quality here. Paying more, out of pocket, for a custom preparation is not evidence you are getting something better than a generic estradiol patch and a micronized progesterone capsule. In most cases it is the same molecules with less verification behind them.

Where this leaves a woman who wants bioidentical hormones

If the appeal of bioidentical hormones is the molecule — estradiol and progesterone rather than older synthetic combinations — you can have that today with a full FDA approval, insurance coverage, verified dosing, and standard labeling. That is the practical takeaway both ACOG and the National Academies point toward.

If the appeal is individualization, it is worth being precise about what individualization means. Real personalization in hormone therapy is choosing route based on your risk profile, choosing dose based on your symptom response, choosing whether you need systemic or only local therapy, and revisiting the plan as symptoms change. None of that requires a custom compound. NAMS's 2022 statement describes benefit-risk as depending on type, dose, route, duration, timing of initiation, and whether a progestogen is needed — all real levers, all available with approved products.

If you fall into one of the genuine gaps — an ingredient allergy, a dose that does not exist commercially, or testosterone therapy for postmenopausal hypoactive sexual desire disorder — compounding is a reasonable path, and the guidelines say so. The point is to arrive there deliberately, knowing which framework you are in and what is and is not established about it.

When to see a healthcare provider

Any vaginal bleeding after you have gone a full year without a period — including light spotting - needs evaluation, whether or not you are on hormone therapy.
New or changed bleeding while on hormone therapy, such as bleeding that starts after months of none, or bleeding that becomes heavy or prolonged. — New or changed bleeding while on hormone therapy, such as bleeding that starts after months of none, or bleeding that becomes heavy or prolonged.
Sudden severe chest pain, shortness of breath, coughing up blood, or pain and swelling in one calf or thigh — call emergency services; these can indicate a blood clot.
Sudden weakness or numbness on one side of the body, face drooping, trouble speaking, sudden severe headache, or sudden vision loss — call emergency services immediately.
New breast lump, skin dimpling or thickening, nipple retraction, or bloody nipple discharge. — New breast lump, skin dimpling or thickening, nipple retraction, or bloody nipple discharge.
On testosterone: deepening voice, hair loss at the scalp, rapidly increasing facial hair, or clitoral enlargement — these signal a dose above the physiologic range and some may not fully reverse.

If symptoms are severe or sudden, contact your primary-care provider, OB/GYN, or a telehealth clinician for same-day evaluation. Browse providers with same-day visits.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

Is the specific product you're prescribing FDA-approved, or is it compounded?
If it's compounded, what is the documented reason an FDA-approved estradiol or progesterone product won't work for me?
I have a uterus — what exactly is protecting my endometrium, and is that progestogen in a form with established endometrial protection?
Will this be filled at a regular pharmacy or a compounding pharmacy, and will my insurance cover it?
If I don't tolerate this dose, how quickly can it be lowered or stopped?
What decision would a saliva or blood hormone level actually change in my treatment plan?
Could low-dose vaginal estrogen treat my symptoms instead of, or alongside, systemic therapy?

Affiliate link Advertiser Disclosure: This site is reader-supported. We may earn an affiliate commission when you sign up for a service through links on our site. This does not influence our editorial recommendations or medical reviews. Read our full disclosure.

Frequently asked questions

Are FDA-approved hormones bioidentical?: Many are. Estradiol patches, gels, sprays, tablets, vaginal creams, inserts, and the vaginal ring all contain 17-beta estradiol, which is molecularly identical to the estrogen your ovaries produced. Micronized progesterone capsules are bioidentical progesterone, and an approved combination capsule pairs estradiol with progesterone. If someone tells you bioidentical hormones require a compounding pharmacy, that is not accurate.
Did ACOG say compounded bioidentical hormones are unsafe?: ACOG's Clinical Consensus recommends FDA-approved hormone therapy over compounded preparations for most women, which is a different statement from declaring compounded hormones unsafe. The objections are that compounded preparations lack verified potency, do not come with standardized labeling and warnings, and have no evidence base supporting the superiority claims made for them. ACOG accepts compounding for a documented allergy to an ingredient in an approved product, or a needed dose or formulation that is not commercially available.
Why do compounding clinics use saliva testing if it isn't validated?: Saliva testing produces a personalized-looking result that supports a custom formulation and a retesting schedule. Clinically, it does not work as a dosing tool: salivary hormone concentrations fluctuate substantially within a single day and do not reliably reflect serum levels. Menopausal hormone therapy is dosed to symptom response, not to a target number. ACOG does not support salivary testing for determining hormone therapy dosing.
Are hormone pellets FDA-approved?: Estradiol and estradiol-testosterone pellets marketed to menopausal women are compounded and not FDA-approved. There is an approved testosterone pellet in the US, but it is approved for men. The specific concern with any pellet is that the dose cannot be reduced or stopped once implanted without a procedure to remove it, and compounded pellets have been associated with hormone levels above the premenopausal physiologic range.
Is progesterone cream a substitute for progesterone capsules?: Not for endometrial protection. If you have a uterus and take systemic estrogen, you need adequate progestogen to prevent the lining from overgrowing. Transdermal and buccal progesterone routes have not been established as providing endometrial protection equivalent to oral micronized progesterone. Compounded creams also carry the additional uncertainty that the delivered dose may not match the labeled dose. Any bleeding after menopause needs evaluation regardless of what you are taking.
Can I get testosterone as a woman in the US without compounding?: Not from an approved female product, because none exists in the US. Women prescribed testosterone receive either a compounded preparation or a measured fraction of a product approved for men. The Global Consensus Position Statement supports testosterone for postmenopausal hypoactive sexual desire disorder specifically, at doses approximating premenopausal physiologic levels, with blood levels checked to confirm the dose has not overshot. It does not support testosterone for fatigue, mood, cognition, or general wellbeing in women.
What about estriol and "Bi-Est" or "Tri-Est" formulas?: Estriol is not an FDA-approved active ingredient in the United States, so any preparation containing it is compounded by definition. Multi-estrogen blends are marketed on the theory that reproducing several estrogens is more physiologic, but the National Academies review found the evidence insufficient to support the clinical utility of compounded bioidentical preparations generally, and that includes these formulas.
Is bioidentical hormone therapy safer than conventional HRT?: The comparison is often made incorrectly. Route and molecule do appear to matter — NAMS's 2022 position statement describes benefit and risk as depending on hormone type, dose, route, duration, timing of initiation, and whether a progestogen is required. But those distinctions apply to approved estradiol and micronized progesterone, which are bioidentical and approved. Being compounded adds no safety advantage; it removes the verification and labeling that approved products carry.
How do I ask whether what I'm being prescribed is FDA-approved?: Ask it as a direct question about the finished product, not the ingredients: "Is this specific product FDA-approved, or is it compounded?" Then ask where the prescription will be filled — a compounding pharmacy name is the practical tell. ACOG's consensus asks clinicians to disclose non-approved status explicitly, so a clear answer is a reasonable expectation, not an awkward request.
If I'm already on compounded hormones and feel fine, should I switch?: Feeling well is meaningful information and not something to discard. The reason to raise it with a clinician is that an approved equivalent usually exists for the same molecules, often costs less, comes with verified dosing, and — if you have a uterus — provides established endometrial protection. That is a conversation about substituting a known quantity for an unverified one, not about stopping treatment. Do not stop or change hormone therapy on your own.

Primary sources

ClearHormones publishes editorial health information for education only — not medical advice.